Coffin-Lowry syndrome (CLS) is an X-linked syndromic form of mental retardation characterized by various skeletal dysmorphisms, moderate to severe mental retardation, and in some cases, psychosis. CLS is caused by loss-of-function mutations of the p90 ribosomal S6 kinase 2 (RPS6KA3) gene encoding a growth factor-regulated serine/threonine kinase, ribosomal S6 kinase 2 (RSK2). We previously identified RSK2 as a novel interacting protein that tonically inhibits 5-HT2A receptor signaling by phosphorylating Ser-314 within the third intracellular loop.
and skeletal malformations (A. Hanauer and I. D. Young, 2002) . Individuals with CLS frequently display the symptoms of autism spectrum disorder as well as psychosis (U. Sivagamasundari et al., 1994) . CLS is caused by a variety of heterogeneous loss-of-function mutations in the ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RPS6KA3) gene, which maps to Xp22.2 (E. Trivier et al., 1996) . Over 150 distinct mutations have been discovered, with most being unique to individual affected families (J. Delaunoy et al., 2001 ; J. P. Delaunoy et al., 2006 ; P. M. Pereira et al., 2010; A. Schneider et al., 2013) . The RPS6KA3 gene encodes the growth factor-regulated serine/threonine kinase, ribosomal S6 kinase 2 (RSK2). Mutations of the RPS6KA3 gene lead to premature termination of translation and/or to loss of phosphotransferase activity of RSK2 (A. Hanauer and I. D. Young, 2002 ; P. M. Pereira et al., 2010) . Global RSK2 knockout (KO) mice display profound growth retardation, progressive bone loss, memory deficits, and cognitive deficiencies (S. D. Dufresne et al., 2001 ; X. Yang et al., 2004; R. Poirier et al., 2007) .
RSK2 is a member of the ribosomal S6 kinase family which includes RSK1-RSK4. The RSK2 protein contains two functional kinase domains: the N-terminal kinase domain belongs to the AGC (protein kinase A, G and C) family, and the C-terminal kinase domain belongs to the CAMK (calcium/calmodulin-dependent protein kinase) family. RSK2 is a multifunctional effector of the mitogen-activated protein kinase (MAPK) signaling pathway (J. Xing et al., 1996) and is phosphorylated and activated by extracellular signal-regulated kinase (ERK) in response to growth factors, polypeptide hormones and neurotransmitters. Upon activation, RSK2 can phosphorylate a variety of substrates both in the cytosol (e.g., Glycogen synthase kinase 3 beta (GSK3β), L1 cell adhesion molecule (L1CAM), Eukaryotic translation initiation factor 4b (eIF4B), BCL2-associated agonist of cell death (BAD) and SH3 and multiple ankyrin repeat domains (SHANK) ) and in the nucleus (e.g., cAMP response element-binding protein (CREB), Estrogen receptor (ER), Nuclear hormone receptor 77 (Nur77), FBJ murine osteosarcoma viral oncogene homolog (c-fos) and Activating transcription factor 4 (ATF4)) to regulate cell proliferation, differentiation and survival (Y. Romeo et al., 2012) .
Loss-of-function of RSK2 in humans leads to Coffin-Lowry syndrome, which includes behavioral characteristics of a schizophrenia-like psychosis in some individuals (R. A. Collacott et al., 1987; U. Sivagamasundari et al., 1994; A. G. Hunter, 2002) . However, it is unknown how RSK2 mutations lead to this psychosis-like condition. In previous studies (D. J. Sheffler et al., 2006) , we discovered that RSK2 exerts a tonic brake on the signaling of a variety of G proteincoupled receptors (e.g., P2Y-purinergic, PAR-1-thrombinergic, 1-adrenergic, and bradykinin-B receptors). We also found that RSK2 directly interacts with the 5-HT2A receptor and phosphorylates intracellular loop 3 at the conserved Ser-314 to attenuate 5-HT2A receptor signaling (R. T. Strachan et al., 2009) . Accordingly, we hypothesized that genetic deletion of the RSK2 gene may lead to an augmentation of 5-HT2A receptor signaling and induction of a psychosis-like behavior in mice. To test this hypothesis, here we used two mouse models: a global RSK2 KO mouse and a newly created conditional RSK2 KO mouse. We found that both global and forebrain-specific deletion of RSK2 augments 5-HT2A receptor signaling and some of the psychotomimetic actions of PCP and amphetamine.
MATERIALS AND METHODS:

Animals
Mice were maintained in a 12-h light/dark cycle with unlimited access to water and laboratory chow. All procedures were conducted in strict compliance with the "Guide for the Care and Use of Laboratory Animals" (Institute of Laboratory Animal Resources, National Research Council, 1996 edition) and approved by the Institutional Animal Care and Use Committee of the University of North Carolina. RSK2 KO mice (C57BL/6J) were generated and provided by Dr.
André Hanauer (Institute of Genetics, and Molecular and Cellular Biology, Illkirch, CEDEX, France) (R. Poirier et al., 2007) .
Creation of a conditional RSK2 KO mouse
Briefly, a targeting vector for the mouse RSK2 gene was constructed. RSK2 exon 4 was flanked by loxP sites, and two positive selection markers flanked by flippase (Flp) recognition target sites FRT (NeoR, neomycin resistance) and F3 (PuroR, Puromycin resistance) were inserted into introns 3 and 4, respectively. The targeting vector was transfected into the TaconicArtemis C57BL/6N Tac ES cell line by Taconic Farms, and homologous recombinant clones were isolated using double positive selection markers. The targeted ES cells were injected into blastocysts to generate chimeras. Chimerism was measured by coat color contribution of ES cells to BALB/C host (black/white). Highly chimeric mice were bred with Flp-Deleter mice (Taconic Farms) to remove the selection markers. The conditional allele (RSK2 flox ) was confirmed by genotyping. The tail DNA was amplified by PCR with a primer pair directed against the third intron (forward primer, 5′-CCTTAAGTTACAACCCTAGCATCC -3′; reverse primer, 5′-TTCCTTTATTACAGCCAAGACTCC -3′), which generated a 525-bp amplicon in the conditional allele and a 353bp amplicon in the wild type allele. Mice carrying a conditional allele were then backcrossed to the C57 BL/6 mice for more than 10 generations.
To generate forebrain-selective RSK2 KO mice, homozygous male EMX1-Cre transgenic mice (Emx1 tm1(cre)Krj , Jackson Labs) were crossed with heterozygous female RSK2 flox/+ mice. All offspring will contain Cre recombinase transgene and since the RSK2 gene is located on the X chromosome, half of the male offspring will contain RSK2 flox allele and half will contain the WT allele. To detect the Cre recombinase transgene, PCR was carried out using the primers 5′-GCGGTCTGGCAGTAAAAACTATC-3′ and 5′-GTGAAACAGCATTGCTGTCACTT-3′, which generated a 102-bp amplicon from the Cre-coding region.
Quantitative reverse transcriptase-PCR
EMX-RSK2 KO and littermate control mice were injected with the 5-HT2-selective agonist 2,5-dimethoxy-4-iodoamphetamine (DOI, 0.5 mg/kg, i.p.) and after 1 h, mice were euthanized, and total RNA was immediately isolated from micro-dissected frontal cortex tissue using Trizol (Invitrogen, Carlsbad, CA, USA). 10 μg of RNA was treated with DNAse (DNA-free, Ambion, Austin, TX, USA), and first strand complementary DNA was synthesized from 2 μg of the DNase-treated RNA using the Superscript III RNase H Reverse Transcriptase kit (Invitrogen), with random hexamer primers (Invitrogen). Mouse c-Fos complementary DNA was amplified using Power SYBR Green PCR master mix (Applied Biosystems, Invitrogen, Carlsbad, CA, USA) in the 7500 Real-time PCR System (Applied Biosystems). The relative amount of c-Fos specific mRNA was determined by normalizing with β-actin mRNA present in the same samples and is expressed as fold above the saline-treated littermate control mice. The following genespecific primers were used in PCR-mouse c-Fos: sense 5′-CAACACACAGGACTTTTGCG-3′, anti-sense 5′-GGAGATAGCTGCTCTACTTTG-3′; mouse β-actin: sense 5′-TGTTACCAACTGGGACGACA-3′; anti-sense 5′-CTGGGTCATCTTTTCACGGT-3′.
Western blot
Animals were sacrificed, and prefrontal cortex samples were harvested. The sample tissues were homogenized in ice-cold RIPA buffer (50mM Tris-Cl, pH 8.0; 150mM NaCl, 0.1% SDS, 1%
NP-40, 0.5% Na-deoxycholate, plus protease inhibitor cocktail (50ml RIPA buffer/tablet, Roche)) and allowed to lyse on ice for 30 min. After centrifuging at 25,000 × g for 30min at 4°C, supernatants were transferred to a new tube. 20ug total protein were loaded and separated by SDS-PAGE gel, transferred to PVDF membranes, and probed with rabbit monoclonal anti-RSK2 antibody (1:1,000, Cell Signaling) at 4°C overnight. After three washes, the blot was probed with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (1:2,000, life technology) at room temperature for 1 hr. The blot was washed three times and incubated with chemiluminescent substrate (Thermo Scientific) and imaged in a Kodak Imager. After imaging, the blot was extensively washed and re-probed with mouse monoclonal anti-β-actin antibody
(1:10,000, Sigma).
Immunohistochemistry
Immunohistochemistry was performed as previously described (A. I. Abbas et al., 2009 Tiled images were collected with a Qimaging Retiga-EXi camera (Qimaging, Surrey, BC, Canada). The signal intensity was quantified using Image J software (NIH). Raw images were corrected by subtracting the average intensity value of the background. Three regions of interest (ROIs), 200 by 200 pixels, were randomly selected for layer V and peripheral layers; the mean intensity was then measured for each ROI, and these were averaged for each brain section.
Head-twitch response
Head-twitch response was tested as reported previously (J. A. Allen et al., 2011) . Briefly, animals were transferred to the procedure room and acclimated to the new environment for at least 30min. Animals were injected intraperitoneally (i.p.) with various doses of DOI or vehicle and placed into the center of a Plexiglas cage for 20 min, during which time head-twitch behavior was scored (5 min bins) by an experienced observer blind to genotype and drug treatment. Head-twitch behavior is defined as a rapid rotational jerk of the head, which is different from grooming or scratching behaviors (J. Gonzalez-Maeso et al., 2007) .
Open field test
Exploration in a novel environment was assessed by a two hour trial in an open field (40 cm x 40 cm x 30 cm) crossed by a grid of photobeams (VersaMax system, AccuScan Instruments).
Counts were taken of the number of photobeams broken during the trial in five-minute intervals, with separate measures for horizontal activity (total distance traveled), stereotypy activity (repeated breaking of the same set of photobeams), and vertical activity (rearing movements).
For pharmacological studies, animals were injected IP with either MDL 100907 (0.2 or 0.5 mg/kg) or vehicle (0.9% saline) and placed into the activity box. After 30min, animals were injected IP with PCP or AMPH (6 mg/kg) and immediately returned to the activity box for 90min. Activity was monitored during whole period.
Elevated plus-maze test
Mice were given one 5-min trial on a metal plus-maze, which had two closed arms with walls 20 cm in height, and two open arms. The maze was elevated 50 cm from the floor, and the arms were 30 cm long. Animals were placed on the center section (8 cm x 8 cm), and allowed to freely explore the maze. Arm entries were defined as all four paws entering an arm. Entries and time in each arm were recorded during the trial by a blinded human observer via computer coding.
Accelerating rotarod
Subjects were tested for motor coordination and learning on an accelerating rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL). For the first test session, animals were given three trials, with 45 seconds between each trial. Two additional trials were given 48 hours later. Rpm (revolutions per minute) was set at an initial value of 3, with a progressive increase to a maximum of 30 rpm across five minutes (the maximum trial length). Measures were taken for latency to fall from the top of the rotating barrel in five minute test periods.
Social approach test
The three-chamber social approach test was designed to assess the sociability and the preference of social novelty of animals. All animal behaviors were monitored and analyzed by an automated tracking system (Noldus Ethovision). The test subject was first placed in the middle chamber and allowed to explore for ten minutes. After the habituation period, an unfamiliar C57BL/6J mouse (stranger 1) was placed in one of the side chambers enclosed in a small wire cage. An identical empty wire cage was placed in the opposite side of the chamber. The subject was then allowed to explore three chambers for a ten-minute session and the amount of time subject spent exploring the unfamiliar mouse or empty cage was recorded. At the end of the sociability test, each mouse was further tested for exploration of a new unfamiliar mouse (stranger 2) placed in the previously empty wire cage. Under these conditions the test mouse had a choice between the first, already-investigated mouse (stranger 1) and the novel unfamiliar mouse (stranger 2). The same measures were taken as with the sociability test.
Morris water maze
The Morris water maze task was described in our previous study (H. Zhu et al., 2014) . Briefly, mice were given a visual cue test first to evaluate the visuo-motor abilities and the motivation of the animals. After the visual cue test, mice were trained in the hidden platform test as described previously. Each animal was given 4 trials per day, across 6 days, to learn the location of the submerged platform. The criterion for learning was an average latency of 15 sec or less to locate the hidden platform. After meeting this criterion, mice were then tested for spatial memory during a 1min trial in the pool with the platform removed. Spatial memory was evaluated by measuring the percent of time mice spent in the quadrant where the hidden platform was located.
Fear conditioning
Conditioned fear was evaluated using a Near-Infrared Video Fear Conditioning system (MED Associates, St. Albans, VT). In the training phase, mice received 3 pairings of a 30-sec, 90 dB, 5 kHz tone (conditioned stimulus, CS) and a 2-sec, 0.6 mA foot shock (unconditioned stimulus, US). Contextual memory was evaluated in the original training chamber 24 hours following the training phase, whereas cued memory was evaluated in a new chamber 48 hours following the training phase. Periods of freezing (no movement for 0.5 sec) were automatically measured by the image tracking software (Med Associates, St Albans, VT).
Prepulse inhibition of startle response
The acoustic startle test was used to evaluate reactivity to an auditory stimulus and sensorimotor gating as previously described (J. A. Allen et al., 2011) . Mice were tested with a San Diego Instruments SR-Lab system. Briefly, mice were placed in a small Plexiglas cylinder within a larger, sound-attenuating chamber. The cylinder was seated upon a piezoelectric transducer, which allowed vibrations to be quantified and displayed on a computer. The chamber included a ceiling light, fan, and a loudspeaker for the acoustic stimuli. Background sound levels (70 dB) and calibration of the acoustic stimuli were confirmed with a digital sound level meter (San 
Receptor autoradiography
5-HT2A receptor autoradiography was performed as previous reported (J. A. Allen et al., 2011) .
Briefly, brains were quickly removed, frozen on dry ice, and stored at -80°C until processing. hour at RT in standard binding buffer (50mM TrisHCl, pH 7.4; 10 mM MgCl, 0.1mM EDTA) to determine total binding. Ritanserin (1 uM; 5-HT2A/5-HT2C receptor antagonist) was added to the incubation mixture to determine non-specific binding. Sections were washed (310 min) in icecold binding buffer (50 mM TrisHCl, pH 7.4), rinsed in ice-cold water (to remove residual salts), then air-dried and exposed to hyperfilm (GE Healthscience) for one week. Films were developed and photographed with a digital camera system (Metaview). Image analysis was performed using ImageJ software to define regions of interest (ROI) in cortical layers 5 and 6
and this ROI was transposed onto the non-specific binding images. Average pixel intensities of the nonspecific ROI was subtracted from the total ROI to obtain qualitative specific binding data.
Statistical Analysis
For quantitation of immunoblots, immunostaining, mRNA expression and autoradiography, or other two-group comparisons, two-tailed unpaired t-tests were used to compare whether there is a significant difference between two groups. All behavioral data were analyzed by two-way ANOVA followed by Bonferroni post tests for comparing multiple groups. Comparisons were considered significant if the p-value was <0.05. Figure   1E ). Taken together, locomotion and PPI studies support an enhancement of 5-HT2A-dependent signaling in global RSK2 KO mice.
Generation of forebrain-specific RSK2 KO mice
Given that the global RSK2 KO mouse has many non-neuronal phenotypes due to global RSK2 deletion, we undertook a more targeted approach by generating forebrain-specific conditional RSK2 KO mice. In these mice, exon 4 of the RSK2 gene was flanked by two LoxP sites that are removed by Cre recombinase, leading to a frameshift and premature termination of translation in exon 5. The resulting truncated protein contains only the first 81 amino acids of the RSK2 protein and lacks the kinase domain ( Figure 2A To confirm forebrain-specific disruption of RSK2, we analyzed RSK2 protein expression using Western blot and immunofluorescence microscopy. Western blot results showed that there was a single ~90 kDa band of RSK2 protein in conditional RSK2 mice and EMX Cre/+ RSK2 + control mice, but only a weak band was present in the EMX-RSK2 KO mice ( Figure 2C ).
Immunohistochemistry with the neuron-specific stain NeuroTrace showed that RSK2 was not expressed in cortical (CTX) and hippocampal (HPC) neurons of EMX-RSK2 KO mice ( Figure   2D ), although expression was retained in thalamic neurons (Thal) lacking Cre recombinase ( Figure 2D ). In contrast, RSK2 was expressed in the neurons of all three brain regions in control mice ( Figure 2E ). Taken together, we generated EMX-RSK2 KO mice with forebrain-specific disruption of RSK2.
EMX-RSK2 KO mice exhibit decreased sensitivity to 5-HT2A antagonism
To determine whether forebrain-specific deletion of RSK2 leads to any intrinsic basal behavioral changes, animals were subjected to a battery of neurobehavioral tests in their naïve state. EMX-RSK2 KO mice showed normal growth, body weight, and mating behavior, unlike global RSK2 KO mice that have been reported to display decreases in growth and weight gain (X. Yang et al., 2004 Figure 3A to 3G). Together, these data show no baseline behavioral changes after disruption of RKS2 in the forebrain, distinct from results obtained by others with global RSK2 KO mice.
We next determined whether forebrain-specific RSK2 KO mice exhibit an augmented response to the psychotomimetic drugs PCP and AMPH. As seen in global RSK2 KO mice (Figure 1 ( Figure 4B and 4D ).
We next determined if forebrain-specific deletion of RSK2 decreased the ability of the 5-HT2A
antagonist MDL to normalize PCP-induced disruption of PPI as seen with the global RSK2 KO mice. As shown in Figure 4E , EMX-RSK2 KO mice exhibited both baseline and PCP-induced changes in PPI that were comparable to control mice. Injection of MDL (0.2 or 0.5mg/kg) 30min
before PCP (6mg/kg) administration normalized PCP-induced disruption of PPI in control mice (F(2,66)=4.818, p=0.0146, two-way ANOVA); whereas it was not effective in EMX-RSK2 KO mice (F(2,84)=0.297, p=0.7446, two-way ANOVA) ( Figure 4F ). Similar to our observations with global RSK2 KO mice ( Figure 1E ), 5-HT2A blockade was less effective at normalizing the psychotomimetic effects of PCP.
5-HT2A signaling is augmented in EMX-RSK2 KO mice
Our previous studies (D. .0337, effect of genotype, F(1,32)=4.538, p=0.0409, two-way ANOVA) ( Figure 5D ). Thus, forebrain-specific disruption of the RSK2 gene augments 5-HT2A signaling in vivo.
Next, we tested whether increased 5-HT2A function in EMX-RSK2 KO mice leads to an increased head twitch response (HTR) in animals. The HTR is a reliable and extensively validated behavioral readout for 5-HT2A agonism ( J. A. Allen et al., 2011) and has been shown to be elevated in PKC KO mice (B. J. Bowers et al., 2006) . Following DOI (0, 0.5, 1.0 mg/kg) administration, both genotypes showed a dose-dependent increase in HTR over a 20 min period ( Figure 5E ). Notably, the HTR was significantly greater in EMX-RKS2 KO mice compared to littermate control mice (interaction of genotype and dose, F(2,36)=3.613, p=0.0372, effect of genotype, F(1,36)=9.827, p=0.0057, two-way ANOVA) ( Figure 5E ). Since DOI is a 5-HT2A
receptor partial agonist, we also treated mice with the full agonist 5-hydroxytryptophan (5-HTP) to fully activate this signaling pathway. Following 5-HTP (0, 50, 100, 200 mg/kg) administration, the HTR was increased in both genotypes ( Figure 5F ). Similar to DOI, we observed that 5-HTP (100 and 200 mg/kg) elicited a significantly greater HTR in EMX-RSK2
KO mice compared to the control mice (interaction of genotype and dose, F(3,24)=4.582, p=0.0113, effect of genotype, F(1,24)=19.57, p=0.0022, two-way ANOVA) ( Figure 5F ). Taken
together, these results demonstrate that forebrain-specific RKS2 disruption potentiates 5-HT2A function in vivo.
EMX-RSK2 KO mice show no alteration in 5-HT2A receptor expression
We next quantified 5-HT2A receptor expression via receptor autoradiography ( 125 I-DOI binding)
and immunofluorescence microscopy to determine if altered receptor expression could account for the increased signaling in EMX-RSK2 KO mice. As shown in Figure 6A for both genotypes, we observed a high density of 125 I-DOI labeling in layer V of the cerebral cortex which is known to contain high levels of 5-HT2A receptors (A. Pazos et al., 1985; J. F. Lopez-Gimenez et al., 1997) . Quantitation revealed no significant difference between genotypes (t(8)=0.2448, p=0.8128, unpaired t-test) ( Figure 6C ) and complete displacement by ritanserin--a 5-HT2A/5-HT2C selective antagonist--confirmed the specificity of 125 I-DOI binding. The expression of 5-HT2A receptors in frontal cortex was further confirmed by immunostaining with a selective and previously validated 5-HT2A receptor antibody (P. N. Yadav et al., 2011) . We observed an overall diffuse laminar staining in the cerebral cortex and characteristic intensive band staining in the apical dendritic trunk and secondary branches of layer V pyramidal cells ( Figure 6B ). In agreement with the 125 I-DOI labeling, no significant difference was observed in the intensity of layer V and peripheral layer staining between EMX-RSK2 KO mice and littermate control mice (F(1,8)=1.147, p=0.3153, two-way ANOVA) ( Figure 6D ). Taken together, our results demonstrate that augmented 5-HT2A receptor signaling in EMX-RSK2 KO mice was not due to altered 5-HT2A receptor expression in the forebrain.
DISCUSSION:
The main findings of this paper are that (1) RSK2 exerts a tonic brake on 5-HT2A signaling in vivo, and (2) that genetic deletion of RSK2 augments some of the psychotomimetic actions of amphetamine and PCP. Importantly, for these studies we generated a conditional RSK2 KO mouse to demonstrate that these behavioral effects can be attributed to selective deletion of RSK2 from the forebrain. These results provide compelling support for the hypothesis that RSK2
modulates 5-HT2A signaling in vivo, dysregulation of which augments psychotomimetic drug actions.
As part of a large and ongoing effort to identify novel regulators of 5-HT2A receptor signaling pathways, we identified RSK2 as a novel interacting protein that directly phosphorylates Ser-314 knockout mouse model (P. Marques Pereira et al., 2008) . It is also possible that defects in neuronal growth due to impaired RSK2-dependent PLD1 activity contribute to the increased responsiveness of EMX-RSK2 KO mice to psychostimulants (M. R. Ammar et al., 2013) , although the behavioral similarities between WT mice and forebrain deleted RSK2 mice argue against this possibility. More generally, our observation that 5-HT2A receptor dysregulation is pro-psychotic and renders antagonists less effective is consistent with other in vivo studies in which 5-HT2A receptor interacting proteins were deleted (e.g., Cav1 and PSD-95 KO mice) (A.
I. Abbas et al., 2009; J. A. Allen et al., 2011) .
In the present study, we used multiple pharmacological approaches to evaluate 5-HT2A receptor signaling in RSK2 mutant mice. In the first approach, we used the 5-HT2A receptor selective antagonist MDL 100907 to block PCP-and AMPH-induced locomotion, which is typically used to evaluate 5-HT2A signaling in vivo. In a second approach, we used the potent hallucinogen DOI to activate 5-HT2A receptors in c-fos and HTR studies. Although DOI can activate both 5-HT2A
and 5 Animals were injected with MDL (0.2mg/kg) and placed into open field chambers, 30 min later mice were injected with 3mg/kg AMPH and the total distance traveled was determined. E. PCP disrupted the sensorimotor gating in both genotypes in a comparable manner. Animal received vehicle, 4mg/kg or 6 mg/kg PCP, and then followed by measuring the acoustic startle response.
PCP significantly disrupted prespulse inhibition in control mice (F(2,64)=7.503, p=0.0021, twoway ANOVA; n=12) and EMX-RSK2 KO mice (F(2,82)=10.48, p=0.0002, two-way ANOVA; n=15) . F. Forebrain-specific disruption of RSK2 gene significantly decreased the effectiveness of MDL on normalizing the PCP-induced disruption of sensorimotor gating. Animal received vehicle, 6mg/kg PCP, 0.2mg/kg MDL + 6mg/kg PCP or 0.5mg/kg MDL + 6mg/kg PCP. MDL normalized the disruption of PPI by PCP in control mice (F(2,66)=4.818, p=0.0146, two-way ANOVA; n=12), but it has no effect in EMX-RSK2 KO mice (F(2,84)=0.297, p=0.7446, twoway ANOVA; n=15). * p<0.05, ** p<0.01, *** p<0.001. 
